Medullary Thyroid Carcinoma
📧 Sign up to get email alerts when something new happens for Medullary Thyroid Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) [Phase 1, Phase 2]
LIBRETTO-001 is a Phase 1/2 trial of selpercatinib in RET fusion–positive advanced solid tumors, including non-small cell lung cancer and me…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) [NA]
A clinical trial update shows ongoing recruitment for an individualized mRNA neoantigen vaccine, mRNA-0523-L001, to treat several advanced e…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Cancer and Blood Pressure Management, CARISMA Study [NA]
An ECOG-ACRIN clinical trial update on the CARISMA study, investigating cancer care with blood pressure management in patients with cardiova…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Natural History Study of Children and Adults With Medullary Thyroid Cancer
This clinical trial entry describes a natural history observational study of medullary thyroid carcinoma that is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management
An update on an ongoing clinical trial from MD Anderson investigating the natural history of medullary thyroid carcinoma to inform managemen…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-02-27EMA Authorised: Cometriq (cabozantinib) — Ipsen Pharma
The European Medicines Agency authorised Cometriq (cabozantinib) for thyroid neoplasms, with Ipsen Pharma as the marketing authorisation hol…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC [Phase 3]
Phase 3 clinical trial evaluating CTR-FAPI-guided precision surgery for newly diagnosed medullary thyroid carcinoma is currently recruiting.
-
FDA approval · 2026-01-27FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation.
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers [NA]
This document describes a patient decision aid to help individuals with medullary thyroid carcinoma and their caregivers decide when to star…
-
CLINICAL_TRIALS trial_result · 2026-01-06Clinical Trial Update: A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors [Phase 1, Phase 2]
This phase 1/2 clinical trial update reports results for selpercatinib in pediatric participants with advanced solid tumors and primary CNS …
-
EMA approval · 2025-12-08EMA Authorised: Caprelsa (vandetanib) — Sanofi B.V.
The European Medicines Agency authorised Caprelsa (vandetanib) for thyroid neoplasms, including medullary thyroid carcinoma, with Sanofi B.V…
-
CLINICAL_TRIALS trial_result · 2025-11-28Clinical Trial Update: Study of ACC-1898 in Adult Participants With Advanced Solid Tumors [Phase 1]
Phase 1 study update for ACC-1898 in adults with advanced solid tumors; the trial is not yet recruiting.
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) [Phase 2]
Phase 2 clinical trial update assessing tarlatamab (AMG 757) in metastatic/locally advanced small-cell lung cancer and other poorly differen…
-
CLINICAL_TRIALS trial_result · 2025-11-13Clinical Trial Update: Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer [Phase 2]
Phase 2 clinical trial evaluating selpercatinib given before surgery for RET-altered thyroid cancers is currently active but not recruiting.
-
FDA approval · 2025-10-09FDA Approved: COMETRIQ — Supplemental Application (Exelixis, Inc.)
FDA approved a supplemental application for COMETRIQ (cabozantinib) submitted by Exelixis, Inc.
-
CLINICAL_TRIALS research · 2025-10-09Clinical Trial Update: Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the combination of radiation therapy with a DLL3-targeting bispecific T-cell engager in DLL3-expres…
-
FDA approval · 2025-09-23FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)
The FDA notes a supplemental application for Caprelsa (vandetanib) submitted by Genzyme Corporation, related to an update to its approved la…
-
CLINICAL_TRIALS trial_result · 2025-09-02Clinical Trial Update: A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer [Phase 4]
Phase 4 study evaluating two dosing regimens of cabozantinib (XL184) in progressive, metastatic medullary thyroid carcinoma; results have be…
-
CLINICAL_TRIALS research · 2025-08-24Clinical Trial Update: Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC [NA]
A clinical trial update shows ongoing recruitment for a study evaluating the 68Ga-DOTA-CCK-FS PET/CT imaging tracer in medullary thyroid car…
-
CLINICAL_TRIALS research · 2025-07-03Clinical Trial Update: A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations
A prospective cohort trial evaluating pralsetinib or anlotinib for locally advanced or metastatic medullary thyroid carcinoma with RET mutat…
-
CLINICAL_TRIALS research · 2025-07-03Clinical Trial Update: GFRα4 CAR T Cells in MTC Patients [Phase 1]
Phase 1 trial evaluating GFRα4 CAR T cells for metastatic medullary thyroid carcinoma; status is active but not recruiting.
-
FDA approval · 2025-06-26FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation.
-
CLINICAL_TRIALS trial_result · 2025-06-24Clinical Trial Update: Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer [NA]
A completed clinical trial evaluated 18F-PSMA PET/CT imaging in patients with medullary thyroid carcinoma.
-
CLINICAL_TRIALS research · 2025-06-13Clinical Trial Update: DOTATOC PET/CT for Imaging NET Patients
ClinicalTrials.gov entry describes a DOTATOC PET/CT imaging study for neuroendocrine tumors, sponsored by the British Columbia Cancer Agency…
-
CLINICAL_TRIALS trial_result · 2025-05-31Clinical Trial Update: Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 study results show activity and safety of pralsetinib in RET-altered cancers, including non-small cell lung cancer and thyroid can…